4/A: Keros Therapeutics Amends Officer Stock Option Grant

Keros Therapeutics, Inc. filed an amended Form 4 to correct the transaction date for Chief Legal Officer Esther Cho's grant of 80,000 employee stock options.

Summary

• An amendment (Form 4/A) was filed by Keros Therapeutics, Inc. to correct an error in a previously filed Form 4.
• The original Form 4, filed on February 26, 2026, incorrectly stated the "Date of Earliest Transaction" as January 5, 2026.
• The correct "Date of Earliest Transaction" for the stock option grant is February 24, 2026.
• The filing pertains to Esther Cho, Chief Legal Officer, who was granted 80,000 Employee Stock Options.
• The exercise price for these options is $15.52 per share.
• The options have an expiration date of February 23, 2036.
• The vesting schedule for the options is one-fourth (1/4th) on February 24, 2027, with the remainder vesting in twelve substantially equal quarterly installments thereafter, contingent on continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive. The correction of a minor error is a positive for disclosure accuracy, and the underlying option grant is a standard, positive incentive for executive alignment.

Positives

• The grant of 80,000 employee stock options to the Chief Legal Officer aligns her interests with long-term shareholder value.
• The company promptly corrected an administrative error in its SEC filing, demonstrating commitment to accurate disclosure.

Negatives

• An initial error in the "Date of Earliest Transaction" required an amendment, indicating a minor administrative oversight in the original filing process.

Risks

• The value of the stock options is subject to the future performance of Keros Therapeutics, Inc.'s common stock.
• The vesting of options is contingent upon the Reporting Person's continued service to the company.

Future Outlook

The vesting schedule indicates a long-term incentive structure for the Chief Legal Officer, with options vesting over several years, contingent on continued service. This aligns management's future performance with shareholder returns.

Management Comments

• This filing amends and restates the Form 4 filed on February 26, 2026 that erroneously reported a Date of Earliest Transaction of January 5, 2026 due to an error with the filing platform.

Industry Context

StockSavvy.ai notes that equity compensation, such as employee stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This grant to a Chief Legal Officer is consistent with typical executive compensation packages aimed at aligning leadership interests with long-term company performance.

Comparison to Industry Standards

• The grant of 80,000 options to a Chief Legal Officer in a biotech company like Keros Therapeutics is within the typical range for executive equity compensation, comparable to grants seen at similar-stage biopharmaceutical companies. For instance, executives at companies like Alnylam Pharmaceuticals or Sarepta Therapeutics often receive substantial option grants as part of their long-term incentive plans, reflecting the high-risk, high-reward nature of the industry.
• The vesting schedule, with a one-year cliff followed by quarterly installments over several years, is a common structure designed to promote executive retention and long-term commitment, mirroring practices at companies such as Moderna or BioNTech.

Stakeholder Impact

• Shareholders: The option grant aligns the Chief Legal Officer's interests with shareholder value creation, potentially leading to better long-term performance. The correction ensures accurate public records.
• Employees: The grant is part of executive compensation, which can set a precedent for other employees' incentive structures.

Next Steps

• One-fourth of the granted options will vest on February 24, 2027.
• The remaining options will vest in twelve substantially equal quarterly installments thereafter, subject to continued service.

Key Dates

Recommendation

This filing is an administrative correction of a previous filing regarding an executive stock option grant. It does not contain new material information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The underlying option grant is a standard compensation practice.

Keywords

Keros Therapeutics, KROS, SEC Form 4/A, Stock Options, Employee Stock Option, Beneficial Ownership, Chief Legal Officer, Esther Cho, Equity Compensation, Vesting Schedule